These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1726 related items for PubMed ID: 19576333

  • 1. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, Sanborn DM, Picard MH, Vlahakes GJ, Mela T, Das S.
    Am J Cardiol; 2009 Jul 01; 104(1):128-32. PubMed ID: 19576333
    [Abstract] [Full Text] [Related]

  • 2. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA, Spencer WH, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, Leman RB, Wharton JM, Gold MR.
    J Am Coll Cardiol; 2008 Nov 18; 52(21):1718-23. PubMed ID: 19007692
    [Abstract] [Full Text] [Related]

  • 3. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T, Obergassel L, Lieder F, Leuner C, Strunk-Mueller C, Meyer Zu Vilsendorf D, Beer G, Kuhn H.
    Pacing Clin Electrophysiol; 2005 Apr 18; 28(4):295-300. PubMed ID: 15826262
    [Abstract] [Full Text] [Related]

  • 4. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
    McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, Schaff HV, Tajik AJ, Gersh BJ.
    Eur Heart J; 2007 Nov 18; 28(21):2583-8. PubMed ID: 17483110
    [Abstract] [Full Text] [Related]

  • 5. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.
    Rev Esp Cardiol; 2006 Jun 18; 59(6):537-44. PubMed ID: 16790196
    [Abstract] [Full Text] [Related]

  • 6. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG, Dees H, Dobran I, Hennersdorf M, Perings C, Heydthausen M, Winter J, Strauer BE.
    Z Kardiol; 2000 Jun 18; 89 Suppl 3():194-205. PubMed ID: 10810803
    [Abstract] [Full Text] [Related]

  • 7. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A, Małecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Ruzyłło W, Szwed H.
    Kardiol Pol; 2005 Oct 18; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [Abstract] [Full Text] [Related]

  • 8. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP, Adragão PP, Santos KR, Morgado FB, Cavaco DM, Rossi R, Abecasis M, Neves JP, Bonhosrst D, Gomes JL, Gomes RS.
    Rev Port Cardiol; 2005 Mar 18; 24(3):407-15. PubMed ID: 15929624
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA, Spirito P.
    N Engl J Med; 2000 Feb 10; 342(6):365-73. PubMed ID: 10666426
    [Abstract] [Full Text] [Related]

  • 10. [Interventional treatment in hypertrophic cardiomyopathy].
    Gietzen FH, Schümmelfeder J, Neuser H, Brunn J, Schumacher B, Kerber S.
    Herz; 2005 Mar 10; 30(2):102-10. PubMed ID: 15875098
    [Abstract] [Full Text] [Related]

  • 11. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.
    J Cardiovasc Electrophysiol; 2010 Aug 01; 21(8):883-9. PubMed ID: 20132378
    [Abstract] [Full Text] [Related]

  • 12. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S, Haverkamp W, Borggrefe M, Breithardt G, Bocker D.
    Europace; 2009 Mar 01; 11(3):289-96. PubMed ID: 19095687
    [Abstract] [Full Text] [Related]

  • 13. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment.
    Leonardi RA, Kransdorf EP, Simel DL, Wang A.
    Circ Cardiovasc Interv; 2010 Apr 01; 3(2):97-104. PubMed ID: 20197511
    [Abstract] [Full Text] [Related]

  • 14. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, Ruskin JN, Moss AJ, MADIT-II Investigators.
    J Am Coll Cardiol; 2005 Nov 01; 46(9):1712-20. PubMed ID: 16256874
    [Abstract] [Full Text] [Related]

  • 15. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ.
    Heart Rhythm; 2013 Feb 01; 10(2):214-8. PubMed ID: 23041573
    [Abstract] [Full Text] [Related]

  • 16. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
    Klein G, Lissel C, Fuchs AC, Gardiwal A, Oswald H, Desousa M, Pichlmaier AM, Lichtinghagen R, Geerlings H, Lippolt P, Niehaus M, Drexler H, Korte T.
    Europace; 2006 Aug 01; 8(8):618-24. PubMed ID: 16864615
    [Abstract] [Full Text] [Related]

  • 17. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, Shalaby A, Schaechter A, Subacius H, Kadish A, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators.
    Circulation; 2006 Feb 14; 113(6):776-82. PubMed ID: 16461817
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution.
    ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, Serruys PW.
    Circ Heart Fail; 2010 May 14; 3(3):362-9. PubMed ID: 20332420
    [Abstract] [Full Text] [Related]

  • 19. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
    Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, Zareba W, Steinberg JS, Fischer A, Ruskin J, Andrews ML, MADIT-II Research Group.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):769-73. PubMed ID: 16487843
    [Abstract] [Full Text] [Related]

  • 20. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, Muller JE, Albert CM, TOVA Investigators.
    Circulation; 2004 Mar 23; 109(11):1386-91. PubMed ID: 14993132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 87.